https://scholars.lib.ntu.edu.tw/handle/123456789/561613
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Wu C.-H. | en_US |
dc.contributor.author | Yeh H.-T. | en_US |
dc.contributor.author | Hsieh C.-S. | en_US |
dc.contributor.author | Huang C.-C. | en_US |
dc.contributor.author | Chattopadhyay A. | en_US |
dc.contributor.author | Chung Y.-C. | en_US |
dc.contributor.author | Tu S.-H. | en_US |
dc.contributor.author | Li Y.-H. | en_US |
dc.contributor.author | TZU-PIN LU | en_US |
dc.contributor.author | LIANG-CHUAN LAI | en_US |
dc.contributor.author | Hou M.-F. | en_US |
dc.contributor.author | KING-JEN CHANG | en_US |
dc.contributor.author | MONG-HSUN TSAI | en_US |
dc.contributor.author | ERIC YAO-YU CHUANG | en_US |
dc.creator | Wu C.-H.;Yeh H.-T.;Hsieh C.-S.;Huang C.-C.;Chattopadhyay A.;Chung Y.-C.;Tu S.-H.;Li Y.-H.;Tzu-Pin Lu;Lai L.-C.;Hou M.-F.;Chang K.-J.;Tsai M.-H.;Chuang E.Y. | - |
dc.date.accessioned | 2021-05-21T07:46:13Z | - |
dc.date.available | 2021-05-21T07:46:13Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 20726694 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103843246&doi=10.3390%2fcancers13081821&partnerID=40&md5=9e69d9e3272ab0a5dfb82cefc6429710 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/561613 | - |
dc.description.abstract | The evolutionary trajectories that drive clinical and therapeutic consequences in localized breast cancers (BCs) with ipsilateral breast tumor relapse (IBTR) remain largely unknown. Analyses of longitudinal paired whole-exome sequencing data from 10 localized BC patients with IBTR reveal that, compared to primary breast tumors, homologous recombination (HR) deficiency, inactivation of the HR pathway, chromosomal instability, and somatic driver mutations are more frequent. Furthermore, three major models of evolution in IBTR are summarized, through which relative contributions of mutational signatures shift, and the subclonal diversity expansions are shown. Optimal treatment regimens are suggested by the clinically relevant molecular features, such as HR deficiency (20%) or specific alterations (30%) with sensitivity to available FDA-approved drugs. Finally, a rationale for the development of the therapeutic management framework is provided. This study sheds light on the complicated evolution patterns in IBTR and has significant clinical implications for future improvement of treatment decisions. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.publisher | MDPI AG | - |
dc.relation.ispartof | Cancers | - |
dc.subject | Actionability; Alteration; Clonal architecture; Ipsilateral breast tumor relapse; Whole-exome sequencing | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | tumor marker; adult; aged; algorithm; Article; breast cancer; cancer growth; cancer localization; cancer recurrence; chromosomal instability; clinical article; clinical feature; cohort analysis; evolution; genetic variability; homologous recombination; human; human epidermal growth factor receptor 2 positive breast cancer; human tissue; ipsilateral breast tumor relapse; middle aged; molecular cloning; sensitivity analysis; somatic mutation; triple negative breast cancer | - |
dc.title | Evolutionary trajectories and genomic divergence in localized breast cancers after ipsilateral breast tumor recurrence | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3390/cancers13081821 | - |
dc.identifier.scopus | 2-s2.0-85103843246 | - |
dc.relation.journalvolume | 13 | - |
dc.relation.journalissue | 8 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Institute of Health Data Analytics and Statistics | - |
crisitem.author.dept | Public Health | - |
crisitem.author.dept | Physiology | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Biotechnology | - |
crisitem.author.dept | Center for Biotechnology | - |
crisitem.author.dept | Genome and Systems Biology Degree Program | - |
crisitem.author.dept | Electrical Engineering | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Center for Biotechnology | - |
crisitem.author.dept | Genome and Systems Biology Degree Program | - |
crisitem.author.orcid | 0000-0003-3697-0386 | - |
crisitem.author.orcid | 0000-0002-3913-5338 | - |
crisitem.author.orcid | 0000-0001-9811-3422 | - |
crisitem.author.orcid | 0000-0001-8777-5818 | - |
crisitem.author.orcid | 0000-0003-2530-0096 | - |
crisitem.author.parentorg | College of Public Health | - |
crisitem.author.parentorg | College of Public Health | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Bioresources and Agriculture | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | College of Life Science | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | College of Life Science | - |
顯示於: | 流行病學與預防醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。